Hanbix Tablet 75 mg (Clopidogrel Hydrogen Sulfate)

Adult dosage

○ Adults 1. In patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. In patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start treatment on the day of initiation with a loading dose of 300 mg once daily, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ～ 325 mg should be administered concomitantly with this medicine once daily. 3. In patients with atrial fibrillation, administer this medicine 75 mg orally once daily. Aspirin 75 ～ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate hepatic disease and a bleeding diathesis is limited. This medicine may be administered with or without food.

This medication prevents blood from clotting to prevent thrombosis. When taking this medication, caution is needed for individuals with genetically reduced activity of a specific enzyme (CYP2C19) as the effectiveness may not be sufficient. Also, taking medications that activate certain enzymes in conjunction can increase the risk of bleeding; thus, co-administration should be avoided. Patients with an allergy to this medication or those with bleeding, severe liver damage, nursing mothers, lactose intolerance, etc., should not take this medication. Patients at high risk of bleeding or those scheduled for surgery must consult with a doctor prior to taking this medication and may need to discontinue use 5 to 7 days before surgery. During the use of this medication, if any bleeding symptoms or abnormalities occur, notify healthcare providers immediately, and it may be necessary to check the condition through blood tests, etc. This medication may increase bleeding risk when taken with other medications that also raise bleeding risk; therefore, caution is advised. Pregnant women have a low risk to the fetus when taking this medication, but the risk of bleeding may increase during delivery, so discontinuation 5 to 7 days before delivery is recommended. It is unknown whether this medication is excreted in breast milk; therefore, nursing mothers should consult their doctor regarding whether to continue breastfeeding or to discontinue the medication. Safety and efficacy in children have not yet been established. Older adults may have increased risk of bleeding due to decreased bodily functions; therefore, dose adjustments and careful monitoring are necessary. In case of overdose, bleeding time may be prolonged, and bleeding complications may occur; there is no specific antidote, but platelet transfusions can reverse the drug's effects. This medication should be kept out of the reach of children, and transferring to another container should be avoided.

• Hemorrhage
• gastrointestinal bleeding
• hospitalization required for bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• ocular hemorrhage

This medication must be stored in a tightly sealed container to protect it from air and moisture. Additionally, the medication should be kept in a cool place, away from extreme heat or cold, and it is best stored at room temperature between 1 and 30 degrees Celsius.

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle